- Home
- FRSH vs PTGX Comparison
FRSH vs PTGX Comparison
Compare FRSH & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRSH
- PTGX
- Stock Information
- Founded
- FRSH 2010
- PTGX 2006
- Country
- FRSH United States
- PTGX United States
- Employees
- FRSH N/A
- PTGX N/A
- Industry
- FRSH EDP Services
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- FRSH Technology
- PTGX Health Care
- Exchange
- FRSH Nasdaq
- PTGX Nasdaq
- Market Cap
- FRSH 3.7B
- PTGX 5.0B
- IPO Year
- FRSH 2021
- PTGX 2016
- Fundamental
- Price
- FRSH $11.67
- PTGX $84.78
- Analyst Decision
- FRSH Buy
- PTGX Strong Buy
- Analyst Count
- FRSH 16
- PTGX 9
- Target Price
- FRSH $19.44
- PTGX $86.44
- AVG Volume (30 Days)
- FRSH 3.6M
- PTGX 991.5K
- Earning Date
- FRSH 11-05-2025
- PTGX 11-06-2025
- Dividend Yield
- FRSH N/A
- PTGX N/A
- EPS Growth
- FRSH N/A
- PTGX N/A
- EPS
- FRSH N/A
- PTGX 0.72
- Revenue
- FRSH $810,640,000.00
- PTGX $209,217,000.00
- Revenue This Year
- FRSH $17.01
- PTGX N/A
- Revenue Next Year
- FRSH $13.02
- PTGX $140.23
- P/E Ratio
- FRSH N/A
- PTGX $118.80
- Revenue Growth
- FRSH 18.18
- PTGX N/A
- 52 Week Low
- FRSH $10.51
- PTGX $33.31
- 52 Week High
- FRSH $19.77
- PTGX $93.25
- Technical
- Relative Strength Index (RSI)
- FRSH 56.10
- PTGX 68.68
- Support Level
- FRSH $10.52
- PTGX $76.70
- Resistance Level
- FRSH $11.31
- PTGX $80.43
- Average True Range (ATR)
- FRSH 0.35
- PTGX 2.98
- MACD
- FRSH 0.11
- PTGX 0.41
- Stochastic Oscillator
- FRSH 95.83
- PTGX 86.03
About FRSH Freshworks Inc.
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CS and ITSM categories and has also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and serve their customers and employees. The group derives revenue from North America, Europe, the Middle East and Africa, Asia Pacific, and Other regions.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.